R
Raaj K. Praseedom
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 71
Citations - 2960
Raaj K. Praseedom is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 21, co-authored 65 publications receiving 2037 citations. Previous affiliations of Raaj K. Praseedom include Mahidol University & National Health Service.
Papers
More filters
Journal ArticleDOI
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Laura Broutier,Gianmarco Mastrogiovanni,Monique M A Verstegen,Hayley E. Francies,Lena Morrill Gavarró,Charles R. Bradshaw,George E. Allen,Robert Arnes-Benito,Olga Sidorova,Marcia P. Gaspersz,Nikitas Georgakopoulos,Bon-Kyoung Koo,Sabine Dietmann,Susan E. Davies,Raaj K. Praseedom,Ruby Lieshout,Jan N. M. IJzermans,Stephen J. Wigmore,Kourosh Saeb-Parsy,Mathew J. Garnett,Luc J. W. van der Laan,Meritxell Huch +21 more
TL;DR: The wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease are demonstrated.
Journal ArticleDOI
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N. Primrose,Richard Fox,Daniel H. Palmer,Hassan Malik,Raj Prasad,Darius F. Mirza,Alan Anthony,Pippa Corrie,Stephen Falk,Meg Finch-Jones,Harpreet Wasan,Paul Ross,Lucy Wall,Jonathan Wadsley,Jeff Evans,Deborah D. Stocken,Raaj K. Praseedom,Yuk Ting Ma,Brian R. Davidson,John P. Neoptolemos,Timothy Iveson,James Raftery,Shihua Zhu,David Cunningham,O. James Garden,Clive Stubbs,Juan W. Valle,John Bridgewater +27 more
TL;DR: This randomised, controlled, multicentre, phase 3 study aimed to determine whether adjuvant capecitabine improved overall survival compared with observation following surgery for biliary tract cancer.
Journal ArticleDOI
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
John N. Primrose,Richard Fox,Daniel H. Palmer,Raj Prasad,Darius F. Mirza,David Alan Anthoney,Philippa Corrie,Stephen Falk,Harpreet Wasan,Paul Ross,Lucy Wall,Jonathan Wadsley,T.R. Jeffry Evans,Deborah D. Stocken,Raaj K. Praseedom,David Cunningham,O. James Garden,Clive Stubbs,Juan W. Valle,John Bridgewater +19 more
TL;DR: BILCAP aimed to determine whether capecitabine (Cape) improves overall survival (OS) compared to observation (Obs) following radical surgery in the intention to treat (ITT) population.
Journal ArticleDOI
Meta-analysis of randomized controlled trials comparing laparoscopic with open mesh repair of recurrent inguinal hernia.
TL;DR: There is a paucity of literature concerning the use of laparoscopic surgery for primary inguinal hernia and its role after recurrence, despite suggestions that pooled analysis of existing data is required.
Journal ArticleDOI
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
John Bridgewater,S Pugh,Tom Maishman,Zina Eminton,Jane Mellor,Amy Whitehead,Louise Stanton,Mike Radford,Andrea Corkhill,Gareth Griffiths,Stephen Falk,Juan W. Valle,Derek A. O'Reilly,Ajith K. Siriwardena,Joanne Hornbuckle,Myrddin Rees,Timothy Iveson,Tamas Hickish,O. James Garden,David Cunningham,Tim Maughan,John N. Primrose,Alaaeldin Shablack,Ann O'Callaghan,Anne Moody,Alex Allen,Alison Brewster,Alison Brown,A Mayer,Brian R. Davidson,Chan Ton,Charles Wilson,Charles Lowdell,Charlotte Rees,Christopher Baughan,Clare Barlow,Colin Purcell,David J. Smith,David Tsang,Ewan Brown,Georgina Walker,Hassan Malik,Iain Cameron,Luke Nolan,Marcia Hall,Marjorie Tomlinson,Mark A. Hill,Mark Peterson,Meg Finch-Jones,Nagappan Kumar,Nariman Karanjia,Nasim Ali,Nigel Heaton,Nua Chan Ton,Paul Ross,Raaj K. Praseedom,Robert J. Thomas,Sally Clive,Sarah Slater,Sarah Smith,Satvinder Mudan,Satya Bhattacharya,Sharadah Essapen,Sherif Raouf,Stephen Fenwick,Susan Cleator,Tom Diamond,Vanessa Potter +67 more
TL;DR: An interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with those given chemotherapy alone.